With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

The scarcity of malignant Hodgkin and Reed–Sternberg cells hampers tissue-based
comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid …

Background Intensified systemic chemotherapy has the highest primary cure rate for
advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and …

Hodgkin lymphoma (HL) represents a neoplasm primarily affecting adolescents and young
adults, necessitating the development of precise diagnostic and monitoring tools …

Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the
integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory …

Concurrent administration of pembrolizumab with chemotherapy in untreated classic
Hodgkin lymphoma (CHL) has not been studied previously. To investigate this combination …

State-of-the-art response assessment of central nervous system lymphoma (CNSL) by
magnetic resonance imaging is challenging and an insufficient predictor of treatment …

Investigating prognostic factors in patients with relapsed or primary refractory classical
Hodgkin lymphoma (R/R cHL) is essential to optimize risk-adapted treatment strategies. We …

The rarity of malignant Hodgkin and Reed Sternberg (HRS) cells in classic Hodgkin
lymphoma (cHL) limits the ability to study the genomics of cHL. To circumvent this, our group …

Molecular monitoring of tumor-derived alterations has an established role in the surveillance
of leukemias, and emerging nucleic acid sequencing technologies are likely to similarly …